依那西普联合阿维A治疗重症寻常型银屑病临床观察
被引量:7
摘要
目的:观察依那西普联合阿维A治疗重症寻常型银屑病的临床疗效和安全性。方法:治疗组30例皮下注射依那西普联合口服阿维A,对照组31例仅口服阿维A。治疗12周后评价疗效。结果:治疗组有效率93.33%,对照组为64.52%,两组有效率差异有显著性。结论:依那西普联合阿维A治疗重症寻常型银屑病疗效明显。
出处
《陕西医学杂志》
CAS
2010年第3期319-321,共3页
Shaanxi Medical Journal
参考文献10
-
1Baker BS,Swain AF,Valdimarsson H.T cell subpopulation in the blood and skin of patients with psoriasis.Br J Dermatol,1984,110(1):37-44.
-
2Katz HI,Waalen J,Leach EE.Acitretin in psoriasis:An overview ofadverse effects.J Am Acad Dermatol,1999,41 (3):7-12.
-
3Cather J,Jennifer,Menter A,et al.Novel Therapies for Psoriasis.Am J Clin Dermatol,2002,3(3):159-173.
-
4Arican O,Aral M,Sasmaz S,et al.Serum levels of TND-alpha,IFN-gamma,IL-6,IL-8,IL-12,IL-17,and IL-18 in patients with active psoriasis and clrrelation with disease severity.Mediators Inflamm,2005,(5):273-279.
-
5Esposito M,Mazzotta A,de Felice C,et al.Treatment of erythrodermic psoriasis with etanercept.Br J Dermatol,2006,155(1):156-159.
-
6Papp KA,Tyring S,Lahfa M,et al.A global phase III randomized controlled trial of etanercept in psoriasis:safety,efficacy,and effect of dose reduction.Br J Dermatol,2005,152 (6):1304-1312.
-
7Katugampola RP,Lewis VJ,Finlay AY.The dermatology life quality index:assessing the efficacy of biological therapies for psoriasis.Br J Dermatol,2007,156(5):945-950.
-
8Gottlieb AB,Leonardi CL,Goffe BS,et al.Etanercept monotherapy in patients with psoriasis:A summaty of safety,based on an integrated multistudy database.J Am Acad Dermatol,2006,54(3):92-100.
-
9韩凌,方栩,黄琼,杨勤萍,傅雯雯,郑志忠,顾军,孙建方,许爱娥.注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗中、重度寻常性银屑病疗效观察[J].临床皮肤科杂志,2007,36(11):730-732. 被引量:6
-
10Symmons DP,Silman AJ.Anti-tumor necrosis factor alpha therapy and the risk of lymphoma in rheumatoid arthritis:no clear answer.Arthritis Rheum,2004,50:1703-1706.
二级参考文献7
-
1Cather J, Menter A. Novel therapies for psoriasis[J]. Am J Clin Dermatol, 2002, 3(3): 159-173.
-
2Esposito M, Mazzotta A, de Felice C, et al. Treatment of erythrodermic psoriasis with etanercept[J]. Br J Dermatol, 2006, 155 (1): 156-159.
-
3Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis[J]. N Engl J Med, 2003, 349(21): 2014-2022.
-
4Papp KA, Tyring S, Lahfa M, et al. A global phase Ⅲ randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction[J]. Br J Dermatol, 2005, 152(6): 1304-1312.
-
5Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial[J], lancet, 2001, 357(9271): 1842-1847.
-
6Mrowietz U, Zhu K, Christophers E. Treatment of severe psoriasis with anti-CD25 monoclonal antibodies [J]. Arch Dermatol, 2000, 136(5): 675-676.
-
7Woolacott N, Hawkins N, Mason A. Etanercept and efalizumab for the treatment of psoriasis: a systematic review [J]. Health Technol Assess, 2006, 10(46): 251-252.
共引文献5
-
1孙敬晖,陈泽宇,贾雪松.注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗寻常型银屑病的疗效观察[J].农垦医学,2014,36(4):297-299. 被引量:3
-
2王刚.肿瘤坏死因子α拮抗剂在银屑病治疗中的应用[J].皮肤科学通报,2018,35(1):51-56. 被引量:6
-
3史玉玲.银屑病生物制剂的发展与挑战[J].同济大学学报(医学版),2018,39(2):1-6. 被引量:1
-
4朱愿超,孙雪林,胡欣.银屑病治疗靶向药物的研究进展[J].中国药房,2019,30(4):542-547. 被引量:10
-
5史玉玲.生物制剂在银屑病治疗中的研究进展[J].世界临床药物,2019,40(11):758-764. 被引量:7
同被引文献69
-
1Traczewski P,Rudnicka L.Treatment of systemic lupus erythematosus with epratuzumab.Br J Clin Pharmacol,2011,71(2):175-182.
-
2Davis JC Jr,Totoritis MC,Rosenberg J,et al.Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131)in patients with systemic lupus erythematosus.J Rheumatol,2001,28(1):95-101.
-
3Wolchok JD,Neyns B,Linette G,et al.Ipilimumab monotherapy in patients with pretreatod advanced melanoma:a randomised,double-blind,multicentre,phase 2,dose-ranging study.Lancet Oncol,2010,11(2):155-164.
-
4Calero I,Sanz I.Targeting B cells for the treatment of SLE:the beginning of the end or the end of the beginning? Discov Med,2010,10(54):416424.
-
5U.S.Food and Drug Administration (FDA).FDA approves Benlysta to treat lupus.March 9,2011.
-
6Dillon SR,Harder B,Lewis KB,et al.B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoirmnune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin.ArthritisRes Ther,2010,12(2):R48.
-
7Dall'Era M,Chakravarty E,Wallace D,et al.Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus:results of a multicenter,phase Ib,double-blind,placebo-controlled,dose-escalating trial.Arthritis Rheum,2007,56(12):4142-4150.
-
8Lin WY,Gong Q,Seshasayee D,et at.Anti-BR3 antibodies:a new class of B-cell immunotherapy combining cdlular depletion and survival blockade.Blood,2007,110(12):3959-3967.
-
9Dall'Era M,Wofsy D.Biologic therapy for systemic lupus erythematosus.Discov Med,2010,9(44):20-23.
-
10Chan OC,Kaufman E,Daikh DI.CILA-4Ig substantially prolongs benefits of cyclophosphamide for lupus nephritis.Arthritis Rheum,2000,43:94.
引证文献7
-
1邓丹琪.生物制剂在系统性红斑狼疮和银屑病的应用[J].中华皮肤科杂志,2012,45(1):66-69. 被引量:1
-
2刘翠玲,杨军.依那西普联合他扎罗汀对关节病型银屑病患者皮肤及关节损害的影响[J].实用药物与临床,2014,17(7):845-848. 被引量:2
-
3赵晓冬,王淑安,李昕,杨海龙,王明志,张喜晶.阿维A和常规药物治疗重症银屑病临床效果对比研究[J].中国实用医药,2015,10(9):161-162. 被引量:2
-
4高俊明,王晶,李建凤,于东,胡旭.凉血清热消风散联合穴位注射治疗寻常型银屑病[J].陕西中医,2016,37(12):1630-1631. 被引量:4
-
5杨帆,王华,秦涛,王锁杏,张盼盼.清热凉血消银汤联合阿维A胶囊治疗寻常型银屑病疗效观察[J].陕西中医,2017,38(11):1568-1569. 被引量:13
-
6陈卓林.阿维A治疗重症银屑病的临床疗效[J].临床合理用药杂志,2018,11(30):62-63. 被引量:5
-
7蒙明松.刺血拔罐法联合中药治疗血热型银屑病42例疗效观察[J].世界最新医学信息文摘,2019,0(71):283-283. 被引量:2
二级引证文献27
-
1刘广荣,冯之静.凉血五根汤联合阿维A胶囊治疗寻常型银屑病患者的效果[J].慢性病学杂志,2022(2):261-263. 被引量:1
-
2张梅.凉血熄风汤联合消银汤熏洗对寻常血热型银屑病患者症状积分及PASI评分的影响[J].慢性病学杂志,2021(1):149-151. 被引量:3
-
3燕玲,宛涛,乌云.蒙古高原葱属植物种皮微形态研究[J].内蒙古农业大学学报(自然科学版),2000,21(1):91-95. 被引量:8
-
4陈海江,王芳.甲氨蝶呤联合中药内服在寻常型银屑病中的应用效果分析[J].海峡药学,2013,25(5):135-136. 被引量:2
-
5刘丽,窦海忠.中西医结合治疗银屑病疗效及安全性研究[J].辽宁中医药大学学报,2017,19(11):108-110. 被引量:9
-
6付银锋.消风散合黄连解毒汤治疗湿疹效果观察[J].社区医学杂志,2018,16(2):19-20. 被引量:4
-
7石娴,石年,黄朝卫,邹爱玲.丙酸氯倍他索联合他扎罗汀乳膏治疗寻常型银屑病的疗效与安全性分析[J].医学理论与实践,2018,31(11):1640-1642. 被引量:8
-
8陈卓林.阿维A治疗重症银屑病的临床疗效[J].临床合理用药杂志,2018,11(30):62-63. 被引量:5
-
9李思蒙.阿维A联合喜炎平注射液对斑块型银屑病患者皮损修复及预后的影响[J].皮肤病与性病,2018,40(6):837-839. 被引量:1
-
10乔永立.中西医结合治疗寻常型银屑病60例效果观察[J].皮肤病与性病,2019,41(2):225-226. 被引量:9
-
1朱运海.依那西普联合阿维A治疗重症寻常型银屑病临床观察[J].今日健康,2015,14(4):69-69.
-
2魏铁成.消痔灵治疗腋臭500例[J].新药与临床,1995,14(5):294-294. 被引量:4
-
3李松林.5-Fu皮下注射加冷冻治疗尖锐湿疣96例[J].大肠肛门病外科杂志,1999,5(4):50-50.
-
4杨志刚.转移因子联合0.1%阿达帕林凝胶治疗扁平疣疗效分析[J].临床皮肤科杂志,2004,33(11):704-705. 被引量:11
-
5吴忠刚,苏英伟.冷冻干扰素联合治疗尖锐湿疣22例疗效分析[J].黑龙江医学,2002,26(6):450-450.
-
6李秀贤,黄善赋.阿昔洛韦联合白细胞介素-2治疗复发性生殖器疱疹临床分析[J].临床医学,2013,33(5):96-97. 被引量:1
-
7张皎,袁定芬.斯奇康注射液治疗带状疱疹的疗效观察[J].上海医药,2000,21(9):22-23. 被引量:1
-
8胡荣欣,卢斯汉,李英,杜健群,许婍娴,汤琳.注射用干扰素致重症药疹12例临床分析[J].皮肤性病诊疗学杂志,2014,21(4):300-302. 被引量:4
-
9梁静,焦园园,南燕.CO_2激光联合药物治疗尖锐湿疣疗效观察[J].大家健康(学术版),2014(12):154-155.